ABCB5 and melanoma: Accordingly, high expression of the drug transporter and chemoresistance mediator ABCB5 has been correlated with melanoma progression, and specific targeting of the ABCB5+ population with a monoclonal antibody significantly inhibited tumor growth in patients [64].